Ultrasound-based combination therapy: Potential in urologic cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 1, 2011, Pages 107-113

  Finley, David S ^a   Pouliot, Frederic ^b   Shuch, Brian ^c   Chin, Arnold ^a   Pantuck, Alan ^a   Dekernion, Jean B ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

high intensity focused ultrasound; immunotherapy; kidney cancer; LOFU; low intensity focused ultrasound; prostate cancer; pulsed HIFU

Indexed keywords

ADENOVIRUS VECTOR; BEVACIZUMAB; BORTEZOMIB; C REACTIVE PROTEIN; CANCER VACCINE; DENDRITIC CELL VACCINE; GADOLINIUM; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN G MONOCLONAL ANTIBODY B3 I 111; INTERLEUKIN 10; INTERLEUKIN 6; LIPOSOME; NANOPARTICLE; PLASMID DNA; SERUM AMYLOID A; SORAFENIB; SUNITINIB; TRACER; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BYSTANDER EFFECT; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CRYOABLATION; DNA DAMAGE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; LOW INTENSITY FOCUSED ULTRASOUND; MULTIMODALITY CANCER THERAPY; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; RADIOFREQUENCY ABLATION; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSCRIPTION REGULATION; TUMOR ABLATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ULTRASOUND THERAPY; URINARY TRACT CANCER;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; ULTRASONIC THERAPY; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL; UROLOGIC NEOPLASMS;

EID: 78650478168     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.174     Document Type: Review

References (61)

1. Cole WH. Efforts to explain spontaneous regression of cancer. J. Surg. Oncol. 17, 201-209 (1981).
2. Smith JA Jr, Herr HW. Spontaneous regression of pulmonary metastases from transitional cell carcinoma. Cancer 46, 1499-1502 (1980).
3. Schurmans JR, Blijenberg BG, Mickisch GH, Schröder FH. Spontaneous remission of a bony metastasis in prostatic adenocarcinoma. Urology 155, 653 (1996).
4. Kim H, Park BK, Kim CK. Spontaneous regression of pulmonary and adrenal metastases following percutaneous radio frequency ablation of a recurrent renal cell carcinoma. Korean J. Radiol. 9, 470-472 (2008).
5. Lekanidi K, Vlachou PA, Morgan B, Vasanthan S. Spontaneous regression of metastatic renal cell carcinoma: case report. J. Med. Case Reports 1, 89 (2007).
6. Ablin RJ. Cryoimmunotherapy. Br. Med. J. 3, 476, (1972).
7. Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci. 97, 970-976 (2006).
8. McBride WH, Chiang CS, Olson JL et al. A sense of danger from radiation. Radiat. Res. 162, 1-19 (2004).
9. Hu Z, Yang XY, Liu Y et al. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J. Transl. Med. 5, 1-11 (2007).
10. Liu F, Hu Z, Qiu L et al. Boosting high-intensity focused ultrasound-induced anti-tumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation. J. Transl. Med. 27, 2-12 (2010).
11. Mitragotri S, Kost J. Low-frequency sonophoresis, a review. Adv. Drug Deliv. Rev. 56, 589-601 (2004).
12. Juffermans LJ, Kamp O, Dijkmans PA, Visser CA, Musters RJ. Low-intensity ultrasound-exposed microbubbles provoke local hyperpolarization of the cell membrane via activation of BK(Ca) channels. Ultrasound Med. Biol. 34, 502-508 (2008).
13. Frenkel V, Kimmel E, Iger Y Ultrasound-induced intercellular space widening in fsh epidermis. Ultrasound Med. Biol. 26, 473-480 (2000).
14. Li LY, Yang M, Gao X et al. Prospective comparison of fve mediators of the systemic response after high-intensity focused ultrasound and targeted cryoablation for localized prostate cancer. BJU Int. 104, 1063-1067 (2009).
15. Matin SF, Sharma P, Gill IS et al. Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J. Urol. 183, 333-338 (2010).
16. Xu ZL, Zhu XQ, Lu P, Zhou Q, Zhang J, Wu F. Activation of tumor-infltrating antigen presenting cells by high intensity focused ultrasound ablation of human breast cancer. Ultrasound Med. Biol. 35, 50-57 (2008).
17. Kramer G, Steiner GE, Gröbl M et al. Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infltrating T-cells. Prostate 58, 109-120 (2004).
18. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4, 581-587 (1998).
19. Hancock HA, Cuesta J et al. Investigations into pulsed high-intensity focused ultrasound-enhanced delivery: preliminary evidence for a novel mechanism. Ultrasound Med. Biol. 35, 1722-1736 (2009).
20. Wu F, Zhou L, Chen WR. Host antitumor immune responses to HIFU ablation. Int. J. Hyperthermia 23, 165-171 (2007).
21. Van Leenders GJ, Beerlage HP, Ruijter ET et al. Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate. J. Clin. Pathol. 53, 391-394 (2000).
22. Somersan S, Larsson M, Fonteneau JF et al. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J. Immunol. 167, 4844-4852 (2001).
23. Mulders P, Tso CL, Gitlitz B et al. Presentation of renal tumor antigens by human dendritic cells activates tumor-infltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin. Cancer Res. 5, 445-454 (1999).
24. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991).
25. Satthaporn S, Robins A, Vassanasiri W et al Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother. 53, 510-518 (2004).
26. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679 (2009).
27. Grabmaier K, Vissers JL, De Weijert MC et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int. J. Cancer 85, 865-870 (2000).
28. Mukouyama H, Janezen NK, Hernandez JM et al. Generation of kidney cancer-specifc antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin. Cancer Res. 10, 1421-1429 (2004).
29. Hernández JM, Bui MH, Han KR et al. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin. Cancer Res. 9, 1906-1916 (2003).
30. Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinfammatory cytokines. Cancer Immunol. Immunother. 53, 543-550 (2004).
31. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppresion in cancer. J. Immunol 166, 678-689 (2001).
32. Satthaporn S, Robins A, Vassanasiri W et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother. 53, 510-518 (2004).
33. Hu Z, Yang XY, Liu Y et al. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J. Transl. Med. 5, 34-44 (2007).
34. Hu Z, Yang XY, Liu Y et al. Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem. Biophys. Res. Commun. 335, 124-131 (2005).
35. Matzinger P. The danger model: a renewed sense of self. Science 296, 301-305 (2002).
36. Liu F, Hu Z, Qiu L et al. Boosting high-intensity focused ultrasound-induced anti-tumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation. J. Transl. Med. 8, 1-26 (2010).
37. Tezel A, Paliwal S, Shen Z, Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23, 3800-3807 (2005).
38. Yang R, Reilly CR, Rescorla FJ et al. Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma. J. Pediatr. Surg. 27, 246-251 (1992).
39. Wu F, Wang ZB, Lu P et al. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med. Biol. 30, 1217-1222 (2004).
40. Tsutsui S, Sonoda K, Sumiyoshi K et al Prognostic signifcance of immunological parameters in patients with esophageal cancer. Hepatogastroenterology 43, 501-509 (1996).
41. + T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 63, 1555-1559 (2003).
42. Whiteside T. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16, 3-15 (2006).
43. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today 20, 158-160 (1999).
44. Pardoll D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839 (2003).
45. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional signifcance. Adv. Immunol. 74, 181-273 (2000).
46. Zhou Q, Zhu X, Zhang J, Xu ZL, Lu P, Wu F. Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment. Ultrasound Med. Biol. 34, 81-87 (2008).
47. Osada T, Chong G, Tansik R et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57, 1115-1124 (2008).
48. Khaibullina A, Jang BS, Sun H et al. Pulse high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice. J. Nucl. Med. 49, 295-302 (2008).
49. Bednarski MD, Lee JW, Callstrom MR, Li K. In vivo target-specifc delivery of macromolecular agents with MR-guided focused ultrasound. Radiology 204, 263-268 (1997). (Pubitemid 27281743)
50. Poff JA, Allen CT, Traughber B et al Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology 248, 485-491 (2008).
51. Frenkel V, Etherington A, Greene M et al. Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Acad. Radiol. 13, 469-479 (2006).
52. Fry FJ, Johnson LK. Tumor irradiation with intense ultrasound. Ultrasound Med. Biol. 4, 337-341 (1978).
53. Miller DL, Dou C. The potential for enhancement of mouse melanoma metastasis by diagnostic and high-amplitude ultrasound. Ultrasound Med. Biol. 32, 1097-1101 (2006).
54. Wu F, Wang ZB, Jin CB et al. Circulating tumor cells in patients with solid malignancy treated by high-intensity focused ultrasound. Ultrasound Med. Biol. 30, 511-517 (2004).
55. Bataille N, Vallancien D, Chopin D. Antitumoral local effect and metastatic risk of focused extracorporeal pyrotherapy on Dunning R-3327 tumors. Eur. Urol. 29, 72-77 (1996).
56. Oosterhof GO, Cornel EB, Smits GA, Debruyne FM, Schalken JA. Infuence of high-intensity focused ultrasound on the development of metastases. Eur. Urol. 32, 91-95 (1997).
57. Hancock H, Dreher MR, Crawford N et al. Evaluation of pulsed high intensity focused ultrasound exposures on metastasis in a murine model. Clin. Exp. Metastasis 26, 729-738 (2009).
58. Hueman MT, Dehqanzada ZA, Novak TE et al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specifc antigen recurrence in high-risk prostate cancer patients. Clin. Cancer Res. 11, 7470-7479 (2005).
59. Kouiavskaia DV, Berard CA, Datena E et al. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specifc antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a Phase 2 study in patients with recurrent prostate cancer. J. Immunother. 32, 655-666 (2009).
60. Lubaroff DM, Reynolds CW, Canfeld L et al. Immunologic aspects of the prostate. Prostate 2, 233-248 (1981).
61. Den Brok MH, Sutmuller RP, Nierkens S et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 66, 7285-7292 (2006).